Michael S Rafii1,2, Brian G Skotko3,4, Mary Ellen McDonough3, Margaret Pulsifer4,5, Casey Evans5, Eric Doran6, Gabriela Muranevici2, Patrick Kesslak7, Susan Abushakra8, Ira T Lott6. 1. Alzheimer's Therapeutic Research Institute (ATRI) at University of Southern California, San Diego, CA, USA. 2. Department of Neurosciences, University of California, San Diego, CA, USA. 3. Department of Pediatrics, Down Syndrome Program, Division of Medical Genetics, Massachusetts General Hospital, Boston, MA, USA. 4. Harvard Medical School, Boston, MA, USA. 5. Department of Psychiatry, Psychology Assessment Center, Massachusetts General Hospital, Boston, MA, USA. 6. Department of Pediatrics, University of California, Irvine, CA, USA. 7. ACADIA Pharmaceuticals, San Diego, CA, USA. 8. Alzheon, Inc., Framingham, MA, USA.
Abstract
BACKGROUND:ELND005 (scyllo-Inositol; cyclohexane-1,2,3,4,5,6-hexol) has been evaluated as a potential disease-modifying treatment for Alzheimer's disease (AD). Individuals with Down syndrome (DS) have an increased risk for developing AD dementia. OBJECTIVE: To evaluate the safety and tolerability of ELND005 and to determine its pharmacokinetics (PK) and relationship between PK parameters, safety outcome measures, and exploratory efficacy outcome measures in young adults with DS without dementia. METHODS: This was a prospective, randomized, double-blind, placebo-controlled, parallel-group, three-arm, multicenter Phase II study of the safety and pharmacokinetics of ELND005 administered orally for 4 weeks (ClinicalTrials.gov NCT01791725). Participants who met study eligibility criteria were randomly assigned in a 2 : 1:1 ratio to receive ELND005 at either 250 mg twice daily (BID) or 250 mg once daily (QD) or matching placebo for 4 weeks. RESULTS: There were no apparent treatment group-related trends on cognitive or behavioral measures and there were no SAEs and no deaths in the study. Overall, mean changes from baseline in clinical laboratory parameters, vital sign measurements, electrocardiogram results, and other physical findings were unremarkable. ELND005 accumulation averaged approximately 2-fold with QD dosing, and 3- to 4-fold with BID dosing. CONCLUSION: Overall, treatment of adults with DS with ELND005 at both doses was well tolerated, achieved measurable blood levels and demonstrated no safety findings. Further studies will be needed to test efficacy.
RCT Entities:
BACKGROUND: ELND005 (scyllo-Inositol; cyclohexane-1,2,3,4,5,6-hexol) has been evaluated as a potential disease-modifying treatment for Alzheimer's disease (AD). Individuals with Down syndrome (DS) have an increased risk for developing AD dementia. OBJECTIVE: To evaluate the safety and tolerability of ELND005 and to determine its pharmacokinetics (PK) and relationship between PK parameters, safety outcome measures, and exploratory efficacy outcome measures in young adults with DS without dementia. METHODS: This was a prospective, randomized, double-blind, placebo-controlled, parallel-group, three-arm, multicenter Phase II study of the safety and pharmacokinetics of ELND005 administered orally for 4 weeks (ClinicalTrials.gov NCT01791725). Participants who met study eligibility criteria were randomly assigned in a 2 : 1:1 ratio to receive ELND005 at either 250 mg twice daily (BID) or 250 mg once daily (QD) or matching placebo for 4 weeks. RESULTS: There were no apparent treatment group-related trends on cognitive or behavioral measures and there were no SAEs and no deaths in the study. Overall, mean changes from baseline in clinical laboratory parameters, vital sign measurements, electrocardiogram results, and other physical findings were unremarkable. ELND005 accumulation averaged approximately 2-fold with QD dosing, and 3- to 4-fold with BID dosing. CONCLUSION: Overall, treatment of adults with DS with ELND005 at both doses was well tolerated, achieved measurable blood levels and demonstrated no safety findings. Further studies will be needed to test efficacy.
Entities:
Keywords:
Alzheimer’s disease; Down syndrome; Myo-inositol; amyloid; dementia
Authors: Reisa A Sperling; Clifford R Jack; Sandra E Black; Matthew P Frosch; Steven M Greenberg; Bradley T Hyman; Philip Scheltens; Maria C Carrillo; William Thies; Martin M Bednar; Ronald S Black; H Robert Brashear; Michael Grundman; Eric R Siemers; Howard H Feldman; Rachel J Schindler Journal: Alzheimers Dement Date: 2011-07 Impact factor: 21.566
Authors: Matthew Townsend; James P Cleary; Tapan Mehta; Jacki Hofmeister; Sylvain Lesne; Eugene O'Hare; Dominic M Walsh; Dennis J Selkoe Journal: Ann Neurol Date: 2006-12 Impact factor: 10.422
Authors: Earvin Liang; Pamela Garzone; Jesse M Cedarbaum; Martin Koller; Thao Tran; Victor Xu; Brian Ross; Stanford S Jhee; Larry Ereshefsky; Aleksandra Pastrak; Susan Abushakra Journal: Clin Pharmacol Drug Dev Date: 2013-03-16
Authors: R Boada; C Hutaff-Lee; A Schrader; D Weitzenkamp; T A Benke; E J Goldson; A C S Costa Journal: Transl Psychiatry Date: 2012-07-17 Impact factor: 6.222
Authors: Abdul Waheed Khan; Arif-Ullah Khan; Syed Muhammad Mukarram Shah; Aziz Ullah; Muhammad Faheem; Muhammad Saleem Journal: Evid Based Complement Alternat Med Date: 2019-03-03 Impact factor: 2.629
Authors: Jared D Hoffman; Lucille M Yanckello; George Chlipala; Tyler C Hammond; Scott D McCulloch; Ishita Parikh; Sydney Sun; Josh M Morganti; Stefan J Green; Ai-Ling Lin Journal: PLoS One Date: 2019-08-28 Impact factor: 3.240
Authors: Prachi A Patkee; Ana A Baburamani; Katherine R Long; Ralica Dimitrova; Judit Ciarrusta; Joanna Allsop; Emer Hughes; Johanna Kangas; Grainne M McAlonan; Mary A Rutherford; Enrico De Vita Journal: Neurobiol Dis Date: 2021-03-09 Impact factor: 5.996
Authors: Christy L Hom; Katharine A Kirby; Joni Ricks-Oddie; David B Keator; Sharon J Krinsky-McHale; Margaret B Pulsifer; Herminia Diana Rosas; Florence Lai; Nicole Schupf; Ira T Lott; Wayne Silverman Journal: Brain Sci Date: 2021-09-16
Authors: Heather M Snyder; Lisa J Bain; Adam M Brickman; Maria C Carrillo; Anna J Esbensen; Joaquin M Espinosa; Fabian Fernandez; Juan Fortea; Sigan L Hartley; Elizabeth Head; James Hendrix; Priya S Kishnani; Florence Lai; Patrick Lao; Cynthia Lemere; William Mobley; Elliott J Mufson; Huntington Potter; Shahid H Zaman; Ann-Charlotte Granholm; H Diana Rosas; Andre Strydom; Michelle Sie Whitten; Michael S Rafii Journal: Alzheimers Dement Date: 2020-06-16 Impact factor: 16.655